VST CEO Buys the Dip as Analysts Cut Targets Before Q3 Print

Vistra Corp. reports Q3 results on November 5, and the most striking positioning signal ahead of the print is not from short sellers or options traders: it is the CEO buying his own stock in size at prices the market has since left behind.

President and CEO James Burke made three open-market purchases between August 24 and September 1, picking up 8,665 shares at prices around $135, for a combined outlay of roughly $1.17 million. These were discretionary purchases, not pre-arranged 10b5-1 plan trades. The stock now trades at $138.37, close to where Burke was buying. That contrasts sharply with activity from two other executives: CFO Kristopher Moldovan and EVP Scott Hudson both sold meaningful sums in September and early October, though all of those sales were executed under 10b5-1 plans, making them scheduled disposals rather than fresh directional calls. Net insider activity over the past 90 days runs to roughly negative $15.5 million in value, but strip out the planned sales and the picture is more nuanced.

The analyst community has been busy trimming numbers in the week before this print, all while keeping positive ratings intact. BofA, Wells Fargo, and Scotiabank all cut targets in the days just prior to the October 28 article, and the consensus mean price target has now eased to $206.86, down from $208 cited in the previous note. That still implies roughly a 50% premium to the current share price. Morgan Stanley holds the highest target on the Street at $226. The bear case centers on the $1.6 billion adverse EBITDA hit from commodity price swings and the stock's roughly 30% retreat from its peak. Bulls point to the Cogentrix acquisition boosting EBITDA forecasts by 7% and a stated target of converting 60% or more of adjusted EBITDA into free cash flow from 2026 onward. The analyst-recommendation factor score ranks in the 98th percentile, meaning the Street's collective view remains unusually constructive despite the target reductions.

Short interest is not a meaningful pressure point here. At 3% of the free float, short positions have actually fallen around 4% over both the past week and the past month. Cost to borrow has eased 18% over the week to 0.38%, and availability remains extremely loose at 3,771%, meaning there are far more shares available to lend than currently borrowed. No squeeze dynamic is building. Options positioning has also turned less defensive than usual: the put/call ratio at 1.02 is running below its 20-day average of 1.07, and the z-score of negative 1.57 puts it toward the lower, more call-heavy end of the past month's range.

The Q3 print will test whether Vistra's operational execution, particularly free cash flow conversion and retail margin performance, has held up well enough to close even part of the gap between the stock's current level and where every analyst on the Street thinks it should be.